Feature | January 14, 2014

Enrollment completed in trial of high-risk patients

heart valve repair clinical trial study edwards lifesciences sapien 3
January 14, 2014 — Edwards Lifesciences Corp. announced it received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate a single-arm, non-randomized clinical trial of the Sapien 3 transcatheter aortic heart valve in the treatment of intermediate risk patients with severe symptomatic aortic stenosis.
 
The company also completed enrollment in its U.S. clinical trial studying the Sapien 3 valve in the treatment of high-risk or inoperable patients.
 
The Sapien 3 valve is the only transcatheter heart valve available to U.S. patients that can be delivered through a low-profile 14 French expandable sheath. It also has an outer skirt — a cuff of fabric surrounding the bottom of the frame — to provide a seal to address paravalvular leak. The Sapien 3 valve can be implanted with the transfemoral approach through an incision in the leg, as well as alternative access approaches. It is an investigational device that is not available commercially in any country; Edwards anticipates CE mark approval in the near future.
 
The U.S. trial of the Sapien 3 valve will enroll up to 1,000 patients with a Society of Thoracic Surgeons score of 4 to 8 percent, which indicates the average predicted risk of operative mortality at 30 days. All enrolled patients can receive a Sapien 3 valve.
 
"Last year, we completed enrollment in the first U.S. randomized controlled trial involving intermediate risk patients with severe aortic stenosis,” said Larry Wood, corporate vice president, transcatheter heart valves, Edwards Lifesciences. “This unique dataset of 2,000 patients receiving surgery or transcatheter valve replacement will provide a thorough baseline comparison for this new study of the Sapien 3 valve in intermediate risk patients."
 
For more information: www.edwards.com

Related Content

Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
MSCs, stem cells, end-stageheart failure, retrograde, coronary sinus,
News | Stem Cell Therapies| July 29, 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus...
Feature | Heart Valve Repair| July 28, 2015
Boston Scientific announced CE Mark and U.S. Food and Drug Administration (FDA) clearance for the Safari2 Pre-Shaped...
Products | Guidewires| July 28, 2015
The Safari2 Pre-Shaped Guidewire.
heart failure, Adaptive CRT trial, AdaptivCRT algorithm, readmissions
News | Heart Failure| July 22, 2015
Heart failure patients had a significantly lower chance of being readmitted within 30 days of discharge when treated...
Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA
News | Heart Valve Repair| July 22, 2015
Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
GlobalData, TAVR, Edwards, Medtronic, CoreValve Evolut R, Sapien 3

Sapien 3 image courtesy of Edwards Lifesciences

News | Heart Valve Repair| July 21, 2015
The recent U.S. Food and Drug Administration (FDA) approvals of two next-generation transcatheter aortic valve...
Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
News | Antiplatelet and Anticoagulation Therapies| July 21, 2015
Two companion papers published in Academic Emergency Medicine  address the question of when it is appropriate to...
UNC, biomarkers, severe heart disease, fructosamine, LDL cholesterol, Nichols
News | Cardiac Diagnostics| July 21, 2015
Insulin resistance affects tens of millions of Americans and is a big risk factor for heart disease. Yet, some people...
Feature | Atrial Fibrillation| July 20, 2015
A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with...
Overlay Init